RCEL AVITA Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1762303 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.6%
TTM net income YoY15.3%
TTM EPS YoY18.8%
Revenue 3-yr CAGR31.4%
Net income 3-yr CAGR—
Margins
Gross margin83.7%
Operating margin-58.1%
Net margin-67.1%
FCF margin-51.3%
EBITDA margin-55.7%
Returns
ROE-1,746.3%
ROA-67.1%
ROIC (approx.)-117.7%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets110.5%
Debt / equity—
Current ratio0.67x
Interest coverage-8.33x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue4.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $26.11M | $21.70M | $19.25M | $17.61M | $17.06M | $18.42M | $18.51M | $18.41M |
| Cost of revenue | $4.17M | $3.94M | $3.52M | $3.30M | $3.19M | $3.47M | $2.83M | $2.28M |
| Gross profit | $21.94M | $17.77M | $15.73M | $14.31M | $13.88M | $14.95M | $15.68M | $16.13M |
| R&D expense | $4.70M | $5.08M | $5.63M | $5.69M | $3.75M | $5.12M | $6.28M | $4.85M |
| SG&A expense | $6.31M | $5.97M | $6.06M | $7.09M | $7.23M | $6.67M | $6.39M | $7.12M |
| Operating income | -$2.63M | -$6.86M | -$8.80M | -$10.41M | -$9.15M | -$11.15M | -$11.83M | -$9.96M |
| Interest expense | $1.48M | $1.46M | $1.42M | $1.25M | $1.27M | $1.25M | $1.23M | $1.30M |
| Pretax income | -$6.16M | -$7.63M | -$10.62M | -$11.64M | -$13.17M | -$9.92M | -$13.85M | -$11.57M |
| Income tax | $65,000 | $33,000 | -$11,000 | -$17,000 | $15,000 | $4,000 | $8,000 | $19,000 |
| Net income | -$6.22M | -$7.66M | -$10.61M | -$11.62M | -$13.19M | -$9.92M | -$13.86M | -$11.59M |
| EBITDA | -$2.26M | -$6.47M | -$8.18M | -$9.71M | -$8.73M | -$10.75M | -$11.31M | -$9.55M |
| EPS (basic) | -0.20 | -0.25 | -0.35 | — | -0.46 | -0.38 | -0.53 | — |
| EPS (diluted) | -0.20 | -0.25 | -0.35 | — | -0.46 | -0.38 | -0.53 | — |
| Weighted avg. shares (diluted) | 30.87M | 30.75M | 30.54M | — | 28.39M | 26.37M | 26.25M | — |
| Banking | ||||||||
| Provision for credit losses | $22,000 | $14,000 | $0 | $7,000 | -$11,000 | $1,000 | -$7,000 | -$10,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $10.50M | $9.14M | $8.31M | $10.24M | $15.42M | $12.22M | $14.87M | $14.05M |
| Short-term investments | $0 | $2.00M | $5.95M | $7.94M | $7.89M | $3.47M | $10.95M | $21.84M |
| Receivables | $10.34M | $9.87M | $9.88M | $9.09M | $9.01M | $11.34M | $9.10M | $11.80M |
| Inventory | $4.80M | $5.29M | $6.12M | $6.93M | $7.24M | $7.54M | $8.39M | $7.27M |
| Current assets | $27.68M | $28.39M | $31.65M | $35.49M | $41.37M | $36.25M | $47.97M | $57.00M |
| PP&E, net | $7.36M | $7.68M | $8.21M | $8.63M | $9.88M | $9.69M | $9.89M | $10.02M |
| Intangibles | $5.55M | $5.25M | $5.44M | $5.64M | $5.20M | $5.31M | $5.45M | $5.57M |
| Total assets | $46.79M | $47.78M | $51.54M | $56.39M | $63.73M | $58.13M | $69.56M | $79.71M |
| Current liabilities | $23.04M | $68.71M | $66.67M | $62.68M | $61.83M | $62.60M | $22.96M | $20.16M |
| Short-term debt | $0 | $46.66M | $46.14M | $42.98M | $42.45M | — | — | $0 |
| Long-term debt | $45.48M | — | — | $0 | $0 | $42.22M | $41.46M | $42.24M |
| Total debt | $45.48M | — | — | $42.98M | $42.45M | $42.22M | $41.46M | $42.24M |
| Total liabilities | $77.83M | $75.61M | $74.71M | $73.04M | $70.39M | $70.98M | $74.06M | $74.97M |
| Shareholders' equity | -$31.04M | -$27.84M | -$23.17M | -$16.65M | -$6.67M | -$12.89M | -$4.57M | $4.50M |
| Net debt | $34.98M | — | — | $32.74M | $27.03M | $30.00M | $26.59M | $28.20M |
| Shares outstanding | 30.96M | 30.93M | 30.78M | 30.57M | 30.49M | 26.61M | 26.43M | 26.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$710,000 | -$3.50M | -$10.07M | -$5.44M | -$5.22M | -$10.23M | -$10.31M | -$8.08M |
| Capital expenditure | $111,000 | $108,000 | $19,000 | -$674,000 | $934,000 | $524,000 | $221,000 | $1.61M |
| Free cash flow | -$821,000 | -$3.60M | -$10.09M | -$4.76M | -$6.15M | -$10.75M | -$10.53M | -$9.69M |
| Investing cash flow | $1.89M | $3.89M | $2.04M | $11,000 | -$5.34M | $7.02M | $10.77M | $2.47M |
| Financing cash flow | $182,000 | $437,000 | $6.10M | $248,000 | $13.77M | $559,000 | $363,000 | $1.02M |
| Depreciation & amortization | $365,000 | $385,000 | $627,000 | $700,000 | $421,000 | $400,000 | $521,000 | $409,000 |
| Stock-based compensation | $1.67M | $1.99M | $1.10M | $1.37M | $2.78M | $2.67M | $2.69M | $2.80M |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.